UoE

Awakn Life Sciences Signs MOU with Maps

Retrieved on: 
Wednesday, January 19, 2022
Disability, KARE, Forward-looking statement, PTSD, Research, FSE, News, Alcoholism, Clinical trial, Multidisciplinary Association for Psychedelic Studies, Ketamine, Addiction, MDMA, Safety, University, CEO, MAPS, Disease, UoE, American Journal, Psychiatry, Reduction, The American Journal of Psychiatry, Phrase, AUD, Company, Diagnosis, Education, Conditional sentence, Therapy, Family, Charity Navigator, NEO, Partnership, Pharmaceutical industry, Psychopharmacology

Agreement to Explore a Partnership for MDMA-Assisted Therapy for Treatment of Alcohol Use Disorder in Europe

Key Points: 
  • Under the terms of this MOU, Awakn will explore a data licensing agreement with MAPS to support Awakn's Phase IIb and planned Phase III studies for MDMA-assisted therapy for AUD in Europe.
  • Awakn and MAPS will also assess a partnership to secure marketing authorisation/regulatory approval for the ethical commercialization of MDMA-assisted therapy for the treatment of AUD in Europe.
  • "We're delighted to be entering into this MoU with AWAKN which holds great promise for people suffering from AUD."
  • About Awakn Life Sciences Corp.
    Awakn Life Sciences is a biotechnology company, researching, developing, and delivering psychedelic therapeutics to better treat addiction.

Awakn Life Sciences Announces Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment of Alcohol Use Disorder Trial

Retrieved on: 
Tuesday, January 11, 2022
KARE, Pleasure, Research, Patient, FSE, Mortality, Alcoholism, Ketamine, Addiction, Intellectual property, UoE, American Journal, NHS, Psychiatry, Industry, The American Journal of Psychiatry, AUD, Depression, Risk, Drinking, University of Exeter, NEO, Partnership, University, Pharmaceutical industry, Birth control, Psychopharmacology

Primary and Secondary Endpoints Achieved, Including 86% Abstinence Over 6 Months Post Treatment and No Serious Adverse Events

Key Points: 
  • It was the first controlled trial in the world to investigate Ketamine-Assisted Therapy for the treatment of Alcohol Use Disorder (AUD), the results have been published in the American Journal of Psychiatry.
  • Awakn acquired the intellectual property (IP) to the therapy under license for use in further research, its clinics in Europe, and its partnerships globally.
  • The positive Phase II trial outcome and Awakn's newly formed partnership with the UK National Healthcare Service (NHS) and UoE, paved the way to progress this trial into Phase III.
  • The primary outcomes of the trial were 1) Days abstinent in the 6 months after treatment, 2) Relapse at 6 month follow up.

Awakn Life Sciences Signs MOU with NHS (Devon Partnership NHS Trust) and University of Exeter with a View of Increasing Access to Psychedelic-Assisted Psychotherapy in the UK

Retrieved on: 
Tuesday, November 16, 2021
Eli Lilly and Company, University, News, III, KARE, Psychiatry, The American Journal of Psychiatry, Devon Partnership NHS Trust, Clinical trial, Russell Group, Depression, FSE, Public opinion, DPT, CEO, University of Exeter, Autism, SEDAR, Phrase, Research, Learning, UoE, Forward-looking statement, Ketamine, AUD, Intention, Perception, Partnership, American Journal, Acquisition, Mental health, Biotechnology, Company, Awareness, Person, MOU, Therapy, NHS, Addiction, Psychopharmacology, Review, MDMA, Patient, NEO, Pharmaceutical industry, Security (finance)

With a Focus on Bringing the KARE Phase II a/b Trial (Ketamine-Assisted Psychotherapy for Alcohol Use Disorder) into Phase III

Key Points: 
  • The partnership establishes a framework and strategic relationship to assess NHS organizational readiness for ketamine-assisted psychotherapy.
  • The partnership will also assess how best to accelerate the on-label use of ketamine-assisted psychotherapy to treat AUD at scale.
  • "The signing of the MOU is an important milestone as mental health issues continue to exacerbate globally.
  • About Awakn Life Sciences Corp.
    Awakn Life Sciences is a biotechnology company with clinical operations, developing and delivering psychedelic therapeutics (medicines and therapies) to better treat addiction.

Awakn Life Sciences Announces the Findings from the Phase II A/B Study Are to Be Published in the American Journal of Psychiatry

Retrieved on: 
Thursday, November 4, 2021
Research, Biotechnology, FSE, University, University of Exeter, Ketamine, III, Perception, Patient, SEDAR, KARE, Genta (company), Person, Drinking, Review, American Journal, The American Journal of Psychiatry, Reduction, Public opinion, UoE, Forward-looking statement, Company, Phrase, NEO, Intention, News, Student, Frontiers, Pharmaceutical industry, Audit, Security (finance)

World's First Controlled Study to Investigate Ketamine-Assisted Psychotherapy

Key Points: 
  • The phase II a/b trial had four groups, ketamine with and without therapy, and placebo administered with and without therapy.
  • Professor Morgan commented, "We are delighted that the findings are to be published in the American Journal of Psychiatry.
  • "It helped family wise, relationship wise, in every, every single avenue of my life, It's changed it."
  • About Awakn Life Sciences Corp.
    Awakn Life Sciences is a biotechnology company with clinical operations, developing and delivering psychedelic therapeutics (medicines and therapies) to better treat addiction.

Building the Ultimate Drive-In Experience of the Future

Retrieved on: 
Wednesday, November 11, 2020
American films, Films, Articles, Car culture, Cultural history of the United States, Drive-in theater, UoE, Unidad de Operaciones Especiales, Entertainment, Permanent, Drive

Several entertainment companies and commercial real estate developers have partnered with UOE to provide both semi-permanent and permanent Drive-In theater installations.

Key Points: 
  • Several entertainment companies and commercial real estate developers have partnered with UOE to provide both semi-permanent and permanent Drive-In theater installations.
  • Before the pandemic, UOE was only offering the pop-up, mobile option for drive-ins, while they had begun both semi-permanent and permanent LED Screen installations.
  • Movie watching has been changed forever and a new generation of drive-in theaters are filling the void as families look for ways to enjoy safe entertainment."
  • Ultimate Outdoor Entertainment (UOE) is taking outdoor eventsto the next level.

New Drive-In Movie & Dining Experience from Ultimate & Rooftop

Retrieved on: 
Friday, October 16, 2020
Articles, Entertainment, Human activities, Spanish Navy, Unidad de Operaciones Especiales, Outdoor cinema, UoE, Armature, Movie theater, App, Drive-in theater, Advertising

AUSTIN, Texas, Oct. 16, 2020 /PRNewswire/ -- Ultimate Outdoor Entertainment Tampa, Florida is unveiling a new Drive-In Movie Experience next to some amazing dining options at Armature Works.

Key Points: 
  • AUSTIN, Texas, Oct. 16, 2020 /PRNewswire/ -- Ultimate Outdoor Entertainment Tampa, Florida is unveiling a new Drive-In Movie Experience next to some amazing dining options at Armature Works.
  • Rooftop Cinema Club has partnered with Ultimate Outdoor Entertainment (UOE) to create The Drive-In at Armature Works.
  • Earlier this year, UOE began providing Rooftop with the screens, technology and equipment to add Drive-In Movies to their rooftop cinema experiences.
  • On Wednesday, UOE released the Ultimate Mobile Listening App which will continue to enhance the Drive-In movie experience for today's mobile friendly generation.

New Audio Technology Creating Next Generation of Drive-Ins

Retrieved on: 
Wednesday, October 14, 2020
Instant messaging clients, Videotelephony, Marketing, msn, Software, Advertising, Communication design, UoE, Windows Live Messenger, Engagement marketing

Earlier this summer, UOE began their efforts to create a better listening experience for Drive-In audiences around the country.

Key Points: 
  • Earlier this summer, UOE began their efforts to create a better listening experience for Drive-In audiences around the country.
  • The Ultimate Mobile Listening App enhances the three key elements of audience engagement head-on: Increased Audio Quality, Customized Branding, and Targeted Messaging.
  • In addition to static-free listening, UOE clients hosting Drive-In events can now directly connect to their viewers thru the UOE mobile app.
  • "While we are excited about this new audio technology and further promotional capabilities, the added advertising will be a huge benefit to so many of our clients!